SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

10646	Companies
226482	Keywords
154956	Articles
119883	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 08/29/2025 at 23:50, 9 months 27 days ago

Communiqué de presse : Wayrilz de Sanofi est approuvé aux États-Unis comme premier inhibiteur de BTK pour la thrombocytopénie immune
Wayrilz de Sanofi, premier inhibiteur de BTK pour la thrombocytopénie immune, approuvé aux États-Unis par la FDA. Étude LUNA 3 a montré une réponse plaquettaire rapide et durable pour les patients adultes

FDA Sanofi Wayrilz Inhibiteur BTK Thrombocytopénie Immune
PRESS RELEASE

published on 08/25/2025 at 18:30, 10 months ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 08/18/2025 at 18:35, 10 months 7 days ago

Sanofi publie le nombre total d'actions et de droits de vote pour juillet 2025

Actions Droit De Vote 2025 Sanofi Code De Commerce Français
BRIEF

published on 08/18/2025 at 18:35, 10 months 7 days ago

Sanofi Reports Total Shares and Voting Rights for July 2025

Voting Rights French Commercial Code Shares 2025 Sanofi
PRESS RELEASE

published on 08/18/2025 at 18:30, 10 months 7 days ago

Sanofi: Information concerning the total number of voting rights and shares - July 2025
Sanofi discloses total voting rights and issued shares as per French commercial and stock market regulations. Details available on their website

Voting Rights Shares French Regulations Investor Relations Sanofi
BRIEF

published on 08/14/2025 at 07:05, 10 months 12 days ago

Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE

Sanofi EMA Médicament Orphelin Rilzabrutinib Maladie IgG4
BRIEF

published on 08/14/2025 at 07:05, 10 months 12 days ago

Sanofi's rilzabrutinib granted orphan drug designation in the EU

Sanofi EMA Orphan Drug Rilzabrutinib IgG4 Disease
PRESS RELEASE

published on 08/14/2025 at 07:00, 10 months 12 days ago

Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4
Sanofi obtient la désignation de médicament orphelin pour le rilzabrutinib dans l'UE contre la maladie liée aux IgG4. Étude de phase 2 positive présentée à l'EULAR 2025

États-Unis Sanofi Médicament Orphelin Rilzabrutinib Maladie IgG4
PRESS RELEASE

published on 08/14/2025 at 07:00, 10 months 12 days ago

Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
Sanofi’s rilzabrutinib granted orphan designation in EU for IgG4-related disease. Positive Phase 2 results presented at EULAR 2025 Congress showcasing efficacy and safety profile

Sanofi Rilzabrutinib Orphan Designation IgG4-related Disease EULAR 2025
PRESS RELEASE

published on 08/11/2025 at 18:30, 10 months 14 days ago

Sanofi: Disclosure of trading in own shares

Accesswire

Published on 06/26/2026 at 15:05, 1 hour 56 minutes ago

Vox Royalty Sells I-80 Gold Offtake Stream
Published on 06/26/2026 at 14:05, 2 hours 56 minutes ago

SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 3 hours 1 minute ago

Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 4 hours 1 minute ago

Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 4 hours 16 minutes ago

Northern Dynasty Reports Oral Arguments Held

View all ACCESSWIRE

EQS Group

Published on 06/26/2026 at 16:38, 23 minutes ago

Cairn Homes Plc: Notice of H1 2026 Trading Update
Published on 06/26/2026 at 15:30, 1 hour 31 minutes ago

JMGO Extends Special Savings Beyond Prime Day with N3 Ultimate at Its Best Price Since Launch
Published on 06/26/2026 at 15:23, 1 hour 37 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 06/26/2026 at 15:23, 1 hour 38 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 06/26/2026 at 15:22, 1 hour 39 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Senior plc

Les Echos

Published on 06/26/2026 at 14:44, 2 hours 17 minutes ago

Safran information
Published on 06/26/2026 at 14:44, 2 hours 17 minutes ago

Information Safran
Published on 06/26/2026 at 12:16, 4 hours 45 minutes ago

Rapport semestriel SIEHM au 30 avril 2026
Published on 06/26/2026 at 07:00, 10 hours 1 minute ago

Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 10 hours 1 minute ago

Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel

View all LES ECHOS COMFI WIRE